First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
The oncolytic virus vuso-vec is slapped with its second CRL.
The group impresses in ovarian and endometrial cancers.
Optimum-02 virtually replicates phase 1, and a filing will follow.
After setbacks, cema-cel might have a path to approval in lymphoma.
